Went public 9/22/2000 at $11 per share
Filing Range: 5.0 mil. shares @ $11 to $13
Shares Outstanding: 18.7 mil. shares
Underwriters: UBS Warburg/CIBC World Markets/SG Cowen
Company Counsel: Wilson Sonsini Goodrich & Rosati
Manager Counsel: Dewey Ballantine LLP
Auditor: Pricewaterhouse Coopers LLP
Develops medical instruments and devices for endoscopic treatment of Gastroesophageal Reflux Disease (GERD). The products consist of radiofrequency generators and single-use disposable devices.
U.S. Venture Partners
U.S. Trust Private Equity
Travelers Insurance Co.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 06/01/1998 1 Early Stage 1866.0
2 12/10/1998 4 Expansion 5794.0
3 08/25/1999 5 Later Stage 17741.0
4 05/19/2000 4 Later Stage 11090.0
(Data in $ millions)
Total Revenues: $0.0
Net Income: -14.1